Is Vident International Equity Strategy ETF (VIDI) a Strong ETF Right Now?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 13 2024
0mins
Source: NASDAQ.COM
Overview of Vident International Equity Strategy ETF (VIDI): Launched in 2013, VIDI is a smart beta ETF that aims to outperform the World ETFs segment by utilizing a principles-based selection strategy and balancing risk across developed and emerging markets, with an expense ratio of 0.61% and a 12-month dividend yield of 3.50%.
Comparison with Other ETFs: While VIDI has shown positive performance, investors may also consider lower-cost traditional market cap weighted ETFs like Vanguard Total International Stock ETF (VXUS) and Vanguard FTSE Developed Markets ETF (VEA), which have significantly lower expense ratios and larger asset bases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JAZZ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JAZZ
Wall Street analysts forecast JAZZ stock price to fall
13 Analyst Rating
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 228.570
Low
188.00
Averages
218.92
High
263.00
Current: 228.570
Low
188.00
Averages
218.92
High
263.00
About JAZZ
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Foreign Healthcare Stocks Show Strong Quant Ratings
- Top Quant Ratings: Jazz Pharmaceuticals (JAZZ) leads with a 4.86 Quant score, showcasing its strong competitive position as one of the highest-rated specialty pharma companies globally, driven by a diversified neuroscience and oncology portfolio.
- Pipeline Excellence: AstraZeneca (AZN) follows closely with a 4.75 rating, reflecting the UK giant's exceptional pipeline execution and its status as one of the few mega-cap pharma companies currently favored by the Quant system.
- Focus on Specialty Drugs: Japanese pharma Astellas (ALPMY) and Swedish Orphan Biovitrum (SWOBY) round out the top four with scores of 4.64 and 4.63, respectively, highlighting the significance of specialty and orphan drug pipelines in the foreign healthcare sector's appeal.
- Market Disparity: While the top four stocks excel, Sandoz (SDZNY) and Galderma (GALDY) sit lower on the list with scores of 3.35, serving as a reminder that not all foreign healthcare stocks receive equal treatment from the Quant system, indicating a clear market disparity.
See More
Jazz Pharmaceuticals Reports Strong Q1 Performance
- Performance Growth: Jazz Pharmaceuticals delivered a strong Q1 performance, with broad-based growth across its commercial portfolio, indicating robust competitiveness in the market despite the lack of specific financial data.
- Commercial Portfolio Success: The positive performance across various business segments suggests a diverse product lineup and strong market demand, potentially laying the groundwork for sustained future growth.
- Market Reaction: Investors reacted positively to Jazz Pharmaceuticals' Q1 results, and while detailed data is lacking, the market sentiment appears optimistic regarding the company's future prospects, which may drive stock price appreciation.
- Strategic Implications: The strong quarterly performance not only enhances the company's position in the biopharmaceutical industry but may also attract more investor interest, thereby providing funding support for subsequent business expansion and R&D investments.
See More
Jazz Pharmaceuticals Reports Record Q1 2026 Earnings with $1.1 Billion Revenue
- Record Revenue: Jazz Pharmaceuticals achieved total revenues of $1.1 billion in Q1 2026, marking the highest in the company's history, primarily driven by the outstanding performance of Xywav, Epidiolex, Modeyso, and Zepzelca, indicating strong growth potential in the market.
- Ziihera Regulatory Progress: The FDA has accepted the sBLA for Ziihera and granted priority review, with an expected approval date of August 25, 2026, and management stated they are ready to launch immediately upon approval, enhancing the company's market position in gastric cancer.
- Xywav Sales Growth: Xywav's net product sales increased by 18% to $408 million, with approximately 425 new patients added and around 16,600 active patients, demonstrating strong demand and an expanding customer base for the product.
- Full-Year Financial Outlook: The company reaffirmed its total revenue guidance for 2026 at $4.25 billion to $4.5 billion, despite anticipating increased competition in the sleep business in the second half of the year, while maintaining an optimistic outlook on the growth potential of multiple products.
See More
U.S. Eases Restrictions on Cannabis Medicines, Unlocking Funding Potential
- Funding Flow Outlook: The U.S. Department of Justice's rescheduling of FDA-approved and state-regulated cannabis products facilitates easier access to banking services and tax benefits, which is expected to provide a lifeline to the struggling cannabis industry.
- Accelerated Financing Plans: Ananda Pharma is preparing to raise between $10 million and $20 million in private funding within six months to expedite U.S. regulatory engagement and manufacturing of its non-psychoactive CBD drug.
- Expanded Market Opportunities: IGC Pharma is mid-stage testing a low-dose THC liquid for agitation in Alzheimer's patients, with a market estimated between $1 billion and $10 billion, and the rescheduling is expected to attract more investors despite ongoing banking service limitations.
- Reputation Improvement: BRC Therapeutics' CEO noted that the reclassification has reduced reputational barriers among traditional life sciences investors, potentially lowering development costs and simplifying research processes, thereby advancing cannabis drug development.
See More
Jazz Pharmaceuticals' Ziihera Receives FDA Priority Review
- FDA Priority Review: Jazz Pharmaceuticals' Ziihera has received priority review from the FDA for the first-line treatment of HER2-positive gastric, gastroesophageal junction, and adenocarcinoma, indicating the company's strategic positioning in oncology.
- Supporting Data: The application is backed by positive results from the HERIZON-GEA-01 trial, which evaluated the efficacy of zanidatamab in combination with standard chemotherapy, highlighting the potential market opportunity for this new therapy.
- PDUFA Target Date: The FDA has set a PDUFA target action date of August 25, 2026, and if approved, this could provide Jazz Pharmaceuticals with a new revenue stream, enhancing its competitiveness in the cancer treatment market.
- Stock Performance: Although Jazz's shares closed at $196.52, down 1.72% last Friday, the FDA's priority review may boost investor confidence in the future, potentially driving the stock price upward.
See More
Jazz Pharmaceuticals' Ziihera Receives FDA Priority Review
- FDA Priority Review: Jazz Pharmaceuticals announced that its Ziihera (zanidatamab-hrii) has received FDA Priority Review, with a target action date of August 25, 2026, marking a significant advancement in treatment options for patients with HER2-positive gastric cancer.
- Clinical Trial Support: The application for Ziihera is supported by data from the HERIZON-GEA-01 trial, which involved 914 patients and demonstrated its efficacy when used in combination with standard chemotherapy, potentially changing the treatment paradigm for HER2-positive gastric cancer.
- Breakthrough Therapy Designation: The FDA has granted Ziihera Breakthrough Therapy designation, aimed at expediting its development and review, reflecting the drug's potential to offer substantial improvements on clinically significant endpoints, addressing urgent medical needs for patients.
- Global Clinical Trials: The HERIZON-GEA-01 trial is conducted across approximately 300 trial sites in over 30 countries, evaluating the efficacy of Ziihera in combination with chemotherapy, showcasing its potential for widespread application globally.
See More
Foreign Healthcare Stocks Show Strong Quant Ratings
- Top Quant Ratings: Jazz Pharmaceuticals (JAZZ) leads with a 4.86 Quant score, showcasing its strong competitive position as one of the highest-rated specialty pharma companies globally, driven by a diversified neuroscience and oncology portfolio.
- Pipeline Excellence: AstraZeneca (AZN) follows closely with a 4.75 rating, reflecting the UK giant's exceptional pipeline execution and its status as one of the few mega-cap pharma companies currently favored by the Quant system.
- Focus on Specialty Drugs: Japanese pharma Astellas (ALPMY) and Swedish Orphan Biovitrum (SWOBY) round out the top four with scores of 4.64 and 4.63, respectively, highlighting the significance of specialty and orphan drug pipelines in the foreign healthcare sector's appeal.
- Market Disparity: While the top four stocks excel, Sandoz (SDZNY) and Galderma (GALDY) sit lower on the list with scores of 3.35, serving as a reminder that not all foreign healthcare stocks receive equal treatment from the Quant system, indicating a clear market disparity.
See More
Jazz Pharmaceuticals Reports Strong Q1 Performance
- Performance Growth: Jazz Pharmaceuticals delivered a strong Q1 performance, with broad-based growth across its commercial portfolio, indicating robust competitiveness in the market despite the lack of specific financial data.
- Commercial Portfolio Success: The positive performance across various business segments suggests a diverse product lineup and strong market demand, potentially laying the groundwork for sustained future growth.
- Market Reaction: Investors reacted positively to Jazz Pharmaceuticals' Q1 results, and while detailed data is lacking, the market sentiment appears optimistic regarding the company's future prospects, which may drive stock price appreciation.
- Strategic Implications: The strong quarterly performance not only enhances the company's position in the biopharmaceutical industry but may also attract more investor interest, thereby providing funding support for subsequent business expansion and R&D investments.
See More
Jazz Pharmaceuticals Reports Record Q1 2026 Earnings with $1.1 Billion Revenue
- Record Revenue: Jazz Pharmaceuticals achieved total revenues of $1.1 billion in Q1 2026, marking the highest in the company's history, primarily driven by the outstanding performance of Xywav, Epidiolex, Modeyso, and Zepzelca, indicating strong growth potential in the market.
- Ziihera Regulatory Progress: The FDA has accepted the sBLA for Ziihera and granted priority review, with an expected approval date of August 25, 2026, and management stated they are ready to launch immediately upon approval, enhancing the company's market position in gastric cancer.
- Xywav Sales Growth: Xywav's net product sales increased by 18% to $408 million, with approximately 425 new patients added and around 16,600 active patients, demonstrating strong demand and an expanding customer base for the product.
- Full-Year Financial Outlook: The company reaffirmed its total revenue guidance for 2026 at $4.25 billion to $4.5 billion, despite anticipating increased competition in the sleep business in the second half of the year, while maintaining an optimistic outlook on the growth potential of multiple products.
See More
U.S. Eases Restrictions on Cannabis Medicines, Unlocking Funding Potential
- Funding Flow Outlook: The U.S. Department of Justice's rescheduling of FDA-approved and state-regulated cannabis products facilitates easier access to banking services and tax benefits, which is expected to provide a lifeline to the struggling cannabis industry.
- Accelerated Financing Plans: Ananda Pharma is preparing to raise between $10 million and $20 million in private funding within six months to expedite U.S. regulatory engagement and manufacturing of its non-psychoactive CBD drug.
- Expanded Market Opportunities: IGC Pharma is mid-stage testing a low-dose THC liquid for agitation in Alzheimer's patients, with a market estimated between $1 billion and $10 billion, and the rescheduling is expected to attract more investors despite ongoing banking service limitations.
- Reputation Improvement: BRC Therapeutics' CEO noted that the reclassification has reduced reputational barriers among traditional life sciences investors, potentially lowering development costs and simplifying research processes, thereby advancing cannabis drug development.
See More
Jazz Pharmaceuticals' Ziihera Receives FDA Priority Review
- FDA Priority Review: Jazz Pharmaceuticals' Ziihera has received priority review from the FDA for the first-line treatment of HER2-positive gastric, gastroesophageal junction, and adenocarcinoma, indicating the company's strategic positioning in oncology.
- Supporting Data: The application is backed by positive results from the HERIZON-GEA-01 trial, which evaluated the efficacy of zanidatamab in combination with standard chemotherapy, highlighting the potential market opportunity for this new therapy.
- PDUFA Target Date: The FDA has set a PDUFA target action date of August 25, 2026, and if approved, this could provide Jazz Pharmaceuticals with a new revenue stream, enhancing its competitiveness in the cancer treatment market.
- Stock Performance: Although Jazz's shares closed at $196.52, down 1.72% last Friday, the FDA's priority review may boost investor confidence in the future, potentially driving the stock price upward.
See More
Jazz Pharmaceuticals' Ziihera Receives FDA Priority Review
- FDA Priority Review: Jazz Pharmaceuticals announced that its Ziihera (zanidatamab-hrii) has received FDA Priority Review, with a target action date of August 25, 2026, marking a significant advancement in treatment options for patients with HER2-positive gastric cancer.
- Clinical Trial Support: The application for Ziihera is supported by data from the HERIZON-GEA-01 trial, which involved 914 patients and demonstrated its efficacy when used in combination with standard chemotherapy, potentially changing the treatment paradigm for HER2-positive gastric cancer.
- Breakthrough Therapy Designation: The FDA has granted Ziihera Breakthrough Therapy designation, aimed at expediting its development and review, reflecting the drug's potential to offer substantial improvements on clinically significant endpoints, addressing urgent medical needs for patients.
- Global Clinical Trials: The HERIZON-GEA-01 trial is conducted across approximately 300 trial sites in over 30 countries, evaluating the efficacy of Ziihera in combination with chemotherapy, showcasing its potential for widespread application globally.
See More
